目的 探討康艾注射液聯(lián)合西妥昔單抗治療晚期結直腸癌的臨床療效。方法 選取2016年1月-2017年1月于青島市商業(yè)職工醫(yī)院進行治療的晚期結直腸癌患者76例，根據(jù)治療方案的差別分為對照組（38例）和治療組（38例）。對照組患者靜脈滴注西妥昔單抗注射液，初始劑量為400 mg/（m²·周），滴速≤ 5 mL/min，滴注時間120 min，然后維持250 mg/（m²·周）。治療組在對照組的基礎上靜脈滴注康艾注射液，40 mL加入5%葡萄糖注射液250 mL，1次/d。兩組患者均治療6周。評價兩組患者臨床療效，同時比較治療前后兩組患者生存質量改善情況、血清學指標和不良反應情況。結果 治療后，對照組的客觀緩解率（ORR）和臨床獲益率（CBR）分別為28.95%%、52.63%，均分別顯著低于治療組的50.00%、73.68%，兩組比較差異均具有統(tǒng)計學意義（P<0.05）。治療后，對照組改善率為68.42%，顯著低于治療組的92.11%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者血清血管內皮生長因子（VEGF）、缺氧誘導因子-1α（HIF-1α）和基質金屬蛋白酶-9（MMP-9）水平明顯降低，而IL-2和干擾素-γ（IFN-γ）水平明顯增高，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組上述指標改善情況明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 康艾注射液聯(lián)合西妥昔單抗可有效提高晚期結直腸癌患者機體免疫功能，并可顯著改善患者生活質量，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy of Kang'ai Injection combined with cetuximab in treatment of advanced colorectal cancer. Methods Patients (76 cases) with advanced colorectal cancer in Qingdao Commercial Staff Hospital from January 2016 to January 2017 were divided into control (38 cases) and treatment (38 cases) groups based on different treatments. Patients in the control group were iv administered with Cetuximab Solution for infusion, the initial dosage was 400 mg/(m²·week), the speed ≤ 5 mL/min, and the drip time was 120 min, then maintained the speed at 250 mg/(m²·week). Patients in the treatment group were iv administered with Kang'ai Injection on the basis of the control group, 40 mL added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of life quality, serological indexes and adverse reactions in two groups before and after treatment were compared. Results After treatment, ORR and CBR in the control group were 28.95%% and 52.63%, which were significantly lower than 50.00% and 73.68% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the improvement rate in the control group was 68.42%, which was significantly lower than 92.11% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the VEGF, HIF-1α and MMP-9 levels in two groups were significantly decreased, but IL-2 and IFN-γ levels were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the improvement of these indexes in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Kang'ai Injection combined with cetuximab can improve the immunity in treatment of advanced colorectal cancer, and can effectively improve the quality of life, which has a certain clinical application value.